Epcoritamab plus chemo for high-risk Burkitt lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug called epcoritamab combined with standard chemotherapy (DA-EPOCH-R) for people with a high-risk form of Burkitt lymphoma. The goal is to see if adding epcoritamab improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Burkitt lymphoma at any stage and are considered high-risk (for example, a large tumor, high LDH level, or cancer spread).
- You have not had any treatment yet, or you have had only one cycle of chemotherapy or a short course of steroids/cyclophosphamide.
- You are at least 18 years old and have a good enough heart function (ejection fraction of 45% or higher).
- If you are HIV positive, your viral load must be under control or you will start HIV meds soon.
- You must have at least one measurable tumor (or cancer only in the bone marrow) and adequate liver, kidney, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This study tests whether adding epcoritamab, a new immunotherapy drug, to standard chemotherapy (R-CHOP) can help patients with aggressive B-cell lymphomas. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial tests if adding a new targeted drug called glofitamab to standard chemotherapy works better than chemo alone for people with Burkitt lymphoma or double hit lymphoma. It may be a good option if you are newly diagnosed or if your lymphoma has come back after treatment.
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Hear when a new Adult Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.